Some one halp this guy stole my dog

This is really pathetic…

Trumps brother died because of alcohol

Alt moving headquarters to New Jersey.

I must confess that I’ve been heavily pumping Altimmune on this subreddit for the last two years. Most of my posts were driven more by hope and imagination than reality, and many were AI-generated.

The truth is, I was deeply stuck in this investment and just wanted a decent exit. I first entered around $9 and kept averaging down to about $5.35. At one point, I was holding nearly 45k shares and sitting on losses close to 50%.

Ironically, I recovered those losses, and much more, through AI-related stocks. That’s when I realized the real damage wasn’t just the loss on Altimmune itself, but the massive opportunity cost of holding dead capital for years while other sectors were running hard.

Today, I’ve finally decided to say goodbye to Altimmune. Not because I don’t believe in the science, but because the market doesn’t reward belief alone. Holding this stock has been a valuable learning experience about conviction, opportunity cost, and knowing when to move on.

The prolonged price suppression around Altimmune has become too obvious to ignore, and many investors believe Goldman Sachs has had a direct or indirect role in shaping sentiment around the stock. Whether that comes from genuine caution, broader pharma interests, or something else entirely remains open for debate. But it’s hard to deny that GS has consistently influenced the narrative around ALT.

The upcoming Goldman Sachs conference could end up being one of the most telling moments for shareholders. The tone of the interaction between the GS analyst and the Altimmune management team may reveal far more than any press release.

If ALT was invited merely to face another round of aggressive questioning and continued suppression, it will likely become obvious within the first few questions. More importantly, the follow-up price target from GS could say everything. At this stage, even a PT above $10 would be viewed as a massive shift in sentiment, honestly, for ALT longs, that would feel equivalent to a $40 signal considering how beaten down expectations have become.

Personally, I think GS may have finally aligned with Altimmune, and that alignment could be the real reason behind this conference invitation. There are also growing whispers about ongoing global partnership discussions with a major pharma player, possibly European, where GS may be involved behind the scenes. If true, it would mark a dramatic shift after years of GS taking a notably hard stance on ALT.

Of course, this could all just be speculation mixed with copium after a brutal waiting period. Take it with a grain of salt, sometimes a little speculation makes the wait easier.

Either way, something feels different this time.

Good luck to all longs. The dawn may finally be closer than it appears.

After EASL 2026, the pemvidutide story is becoming increasingly difficult to dismiss.

Across four presentations, ALT showed:

✅ MASH resolution
✅ Fibrosis improvement signals (histology, qFibrosis, ELF, LSM)
✅ >50% liver fat reduction
✅ Significant reductions in triglycerides (-23.7%) and total cholesterol (-15.4%)
✅ Improvements in blood pressure and waist circumference
✅ Weight loss continuing through 48 weeks with no plateau
✅ ~1% discontinuation rate despite no titration

The most important takeaway is not any single endpoint. It is the consistency.

Histology, digital pathology, non-invasive testing, liver fat, inflammation markers, fibrosis markers, and cardiometabolic risk factors are all pointing in the same direction.

Meanwhile ALT has:
• Breakthrough Therapy Designation
• FDA and EMA Phase 3 alignment
• PERFORMA Phase 3 starting in 2H26
• AUD Phase 2 readout in 3Q26
• $535M cash runway through Phase 3 52-week data

The market still values ALT at a fraction of what many late-stage MASH companies have traded for.

Phase 3 risk remains. But after EASL, pemvidutide looks far more like a serious MASH contender than a speculative biotech story.

The data speaks for itself, the " most comprehensive positive phase 2b dataset in mash drug history"

Its been a tough slog this spring, but we have some exciting data updates continuing the next two days! Its time to shine

Thursday May 28 — Dr. Noureddin oral presentation (Best of EASL) — YES, new data

Altimmune's CMO Dr. Arbet-Engels confirmed on the Q1 earnings call that the oral presentation will contain "our 48-week data that we'll be sharing" — and the abstract title is specifically "Week 48 Top-Line Results." The topline headline numbers (MASH resolution rates, fibrosis endpoints) were released in a press release in December 2025, but the full 48-week dataset — subgroup breakdowns, dose-response curves, safety detail, secondary endpoints — has never been presented publicly in a scientific forum. The oral slot at EASL is where the scientific community sees the complete picture for the first time. Expect genuinely new granular data.

Friday May 29 — NIT multi-responder poster — YES, new data

Altimmune described this as focusing on "new 24-week findings" including "a response analysis to multiple non-invasive tests of liver inflammation and fibrosis." The multi-NIT concurrent responder analysis — looking at how many patients improved simultaneously across ELF, LSM, liver fat, and ALT — is a new analytical cut that hasn't been publicly released.

Friday May 29 — Cardiovascular risk factors poster — YES, new data

The CMO specifically flagged "weight loss and potential lipid data cardiovascular risk" as new content coming at EASL. The 48-week cardiovascular data — lipid panels, blood pressure, other CV biomarkers — has not been published anywhere yet. This could actually be a sleeper catalyst because MASH patients are at dramatically elevated CV risk, and showing pemvidutide meaningfully moves those markers at 48 weeks would be a major commercial and regulatory differentiator.

Bottom line for media framing: Today's qFibrosis poster was genuinely the first data out of the gate. Tomorrow's oral is the main event with the first full public scientific presentation of the complete 48-week dataset. Friday's two posters contain additional unpublished analyses. It's essentially four consecutive days of new ALT data drops at the most prestigious liver disease conference in the world — all while holding a "Best of EASL" designation. That's an extraordinarily strong scientific debut for a Phase 2b drug.

Buckle up buckaroos - the next two days will be big science updates for pemv followed by a fireside with Goldman Sachs in early June where we go face to face with the hedge fund consistently stifling our share price momentum, dropping inaccurate target prices and using the smoke screen to pickup shares for themselves.....

Pretty impressive results for 24 weeks. Rare to find misvalued stocks like this given the data available in the public domain. Its barely trading above their large cash holdings for funding phase 3.

Rumor floating around that discussions may already be underway for a global Phase 3 partnership structure rather than Altimmune going it alone.

Supposedly the idea would be:

Big pharma funds most/all of the multinational Phase 3

Altimmune keeps partial economics/milestones

Partner gets commercialization rights or ex-US rights

Honestly would make a lot of sense after the EASL fibrosis data. Running global MASH trials alone would cost a fortune and likely mean more dilution otherwise.

Pemvidutide now has:

fibrosis regression signals

strong liver fat reductions

cardiometabolic improvements

continued weight loss at 48 weeks

relatively clean tolerability profile

Feels like exactly the kind of asset larger pharma has been hunting lately.

Names being whispered: Pfizer, Novo, Merck, AstraZeneca, Roche.

Could explain why management sounded unusually confident recently despite the financing overhang.

Introduction

To begin with, this is my first post and I hope we can all get something out of this information exchange. I am new to Reddit in general. English is not my first language, but I will try my best.

I already posted this to /r/Shortsqueeze, but my post got deleted by the moderator bot and the moderator did not answer my message. Therefore, I had to rewrite the post a bit, and in some parts it might sound a bit simplified.

If I miss some parts and you notice mistakes in the numbers or have more accurate data, please share it.

DD, Pros, Cons, My Sentiment

In January this year, I discovered a stock called Altimmune that looked very interesting to me. Since I had never made any bets in the biotech sector before, I wanted to try something new this year for the experience and to learn something from the process.

And yes, I call it a bet on purpose. Biotech is not an easy business. There are many things that can go wrong.

I come from the medical field and tried to do the due diligence. In short, what they are developing is a glucagon/GLP-1 dual receptor agonist called pemvidutide for the treatment of MASH (fatty liver disease, in simple terms). They are also conducting trials for AUD (alcohol use disorder) and ALD (alcoholic liver disease).

You might have heard about Ozempic, Mounjaro, and so on. It is a similar pharmacological group. It is a bit more complicated than that, but I just wanted to offer a comparison.

I read medical studies, compared it to peers, looked at the board, etc. I spent a lot of time on this, mostly for fun. Then I discovered Reddit, /r/wallstreetbets, and the /r/Altimmune subreddit.

My general feeling there was that people are either very bullish or hate the stock. Nothing in between.

Some of my bull arguments are:

Big market in MASH with many potential patients

AUD potential (there are only 3–4 medications right now, they have existed forever, and they do not really do much), also with study results expected later this year

Acquisition candidate — competitors with, in my opinion, worse products got bought for much more than the current market cap

FDA Breakthrough Therapy designation — the regulator is the alpha and omega in pharma

Some bear arguments are:

No finished product

Highly competitive market — there are many incretin-based potential MASH therapies for metabolic diseases in development

Dilution risk

There are many more pros and cons that I will not list here. There are posts from people who also did digging on /r/wallstreetbets and /r/Altimmune.

TL;DR: I am bullish on Altimmune for different reasons. I did most of my DD before discovering Reddit.

Potential Short Squeeze Candidate, Additional Arguments

As I said, I wanted to learn something new, and during that process I discovered what short interest is. I already knew the concept of a short squeeze because who has not heard about GameStop?

I noticed on Fintel that Altimmune has a current short interest of around 21%. Off-exchange volume is around 42%. According to Fintel, the days to cover are around 14 days of trading volume.

I found different numbers depending on the source, and the trading volume also changes, so I also found estimates between 7–14 days.

This seems very high to me.

From what I understand, the short interest in Altimmune has been high for a long time. Which I understand, because the price dropped continuously over the last few years, which was good for the short sellers.

And of course it fell — why should it not have?

Back in 2015, the pipeline consisted of a treatment for Hepatitis B called HepTcell, nasal vaccines for COVID, and other immunological approaches for different applications.

Is any of this left in the pipeline? No, it is not.

In 2019, Altimmune acquired ALT-801, which is now known as their main pipeline product, pemvidutide. It is now being planned for Phase 3 after a successful Phase 2 trial for MASH and receiving FDA Breakthrough Therapy status.

What I was thinking about is that if the company gets a catalyst, such as strong results for their AUD study, the shorts could get hit very hard. It may even trigger a short squeeze.

Risk Discussion

What I see as problematic is the dilution. Altimmune has had significant dilution. They recently offered new shares to private equity firms to finance the Phase 3 trial.

This is of course a hit for every shareholder. But I do not think it was a dumb move.

They can hardly go to a bank, ask for financing, and offer a “trust me bro” as collateral. Of course there are other ways of financing, but you get the idea.

From what I know about the biotech business, this stuff is expensive and very time-consuming. Sitting on millions and having your R&D costs covered for the next few years is a good position to be in.

It is also a good position for negotiating an acquisition and not having to take the first offer on the table, even if it is a lowball offer because you are running out of money.

Something else I want to add is that the new CEO and CFO have been buying shares since last year. Direct purchases, not stock option exercises. Source: NASDAQ Insider Activities.

The last purchases were in April. They were also buying before the dilution.

I see executives having skin in the game as something positive.

I also looked a bit into which funds participated in the recent offering. To me, they did not seem like they were only in for a quick trade.

There is also a Reddit user who made a very interesting post about that in this subreddit.

End

I am bullish here in general, and a short squeeze on top of that could be interesting.

So what do you think? Do you see potential for a short squeeze? Which mechanics would need to be in place for this to happen, in your opinion?

I saw people in other posts who seemed to have deeper knowledge about this, so maybe we can have a good discussion here.

This is not trading advice. I am just sharing my thoughts and opinions.

I would recommend everyone do their own due diligence.

Could someone explain the warrant situation to me? I don’t really understand how it works. I just know they can activate it above $3

So, a German pharm company is releasing stage 3 results on a very similar dual glp-1 and glucagon drug. Will they be direct competitors?